Obesity treatment has changed more in the last four years than in the forty before it. New GLP-1 medications deliver weight loss once limited to surgery. Older drugs still help the right person.
The hard part is no longer finding options. It is knowing which option fits you, what evidence backs it, and what to ask before you start.
This guide walks through every approved obesity treatment in everyday words. You will see the evidence for each one, who tends to qualify, and the questions that help you pick well.
Treatment is personal. The best plan depends on your health history, your goals, and your preferences. A well-prepared appointment is how you get there.
KEY TAKEAWAYS
- Obesity is a chronic disease defined by a BMI of 30 or higher.
- Lifestyle programs produce 3 to 5 percent weight loss in the first year on their own.
- GLP-1 medications show 8 to 21 percent weight loss in large clinical trials.
- Bariatric surgery remains the most durable option at about 25 to 30 percent.
- Good treatment starts with a real conversation about goals, risks, and trade-offs.
IMPORTANT SAFETY INFORMATION
GLP-1 medications carry a boxed warning for thyroid C-cell tumors based on animal studies. People with a personal or family history of medullary thyroid cancer or MEN 2 should not use them. Pancreatitis, gallbladder disease, and severe nausea are also reported in trials and real-world use.
What you are likely dealing with?
- Every option sounds right for everyone. Ads and social posts rarely say who a treatment fits worst, so nothing feels like it is aimed at you.
- Your doctor has 15 minutes. There is little time to ask everything, and most people leave with questions they never got to.
- You do not want to start and stop. Some obesity treatments only keep working while you take them, and that changes how you plan.
What counts as obesity?
Obesity is a chronic disease, not a willpower problem. The American Medical Association classified it that way in 2013. The change was clinical, and the treatment implications are real.
Doctors use body mass index, or BMI, to define it. BMI is your weight in kilograms divided by your height in meters squared. A BMI of 30 or higher puts you in the obesity range.
The CDC reports that 41.9 percent of US adults meet this threshold (NHANES 2017 to March 2020). Another 30.7 percent are in the overweight range, which is a BMI of 25 to 29.9.
Clinicians split obesity into three classes:
| BMI range | Class |
|---|---|
| 30.0 to 34.9 | Class I |
| 35.0 to 39.9 | Class II |
| 40.0 or higher | Class III (severe) |
BMI is a starting point, not a diagnosis. It does not capture muscle mass, fat distribution, or metabolic health. Your doctor will also check waist size, blood sugar, blood pressure, cholesterol, and liver markers.
Weight-related conditions matter for treatment choices too. Type 2 diabetes, high blood pressure, obstructive sleep apnea, non-alcoholic fatty liver disease, and severe knee osteoarthritis all count. A lower BMI can still justify active treatment when any of these are present.
Your obesity treatment options at a glance
Four broad categories cover every FDA-approved obesity treatment in the United States. You can combine them. Most people end up on more than one at a time.
| Option | Typical weight loss | Time to see results | Who it usually fits |
|---|---|---|---|
| Lifestyle and behavioral therapy | 3 to 5% in a year | 3 to 12 months | Everyone starts here; often combined with other options |
| GLP-1 receptor agonists | 8 to 21% over 14 to 18 months | First 4 to 8 weeks | BMI ≥30, or ≥27 with a weight-related condition |
| Other prescription medications | 3 to 10% over a year | 2 to 6 months | When GLP-1s are not a fit |
| Bariatric surgery | 25 to 30% at 1 year, durable | 3 to 12 months | BMI ≥35, or ≥30 with type 2 diabetes |
| Devices and endoscopic procedures | 10 to 18% at 6 to 12 months | 3 to 6 months | BMI 25 to 40, often a middle path |
The American Association of Clinical Endocrinology (AACE) and The Obesity Society publish treatment guidelines. Both recommend adding medication when lifestyle alone has not produced enough weight loss after six months.
The American Society for Metabolic and Bariatric Surgery (ASMBS) lowered its surgical thresholds in 2022. More people now qualify for surgery than before, including some at a BMI of 30 to 34.9 with metabolic disease.
No single option wins for everyone. Evidence strength, side effects, durability, and personal fit all matter. The sections below walk through each one.
Lifestyle and behavioral treatment
Lifestyle treatment is the foundation of every obesity care plan. It is not a slogan about eating less and moving more. It means structured programs that combine a calorie deficit, physical activity, and behavior change over time.
The Look AHEAD trial enrolled 5,145 adults with type 2 diabetes and obesity. The intensive lifestyle group lost an average of 8.6 percent of body weight at year one. About 4.7 percent of that loss remained at year four (NEJM 2013).
Most structured programs produce 3 to 5 percent weight loss in the first year on their own. That can be clinically meaningful. A 5 percent loss improves blood pressure, blood sugar, and triglycerides for many people.
Intensive Behavioral Therapy (IBT) for obesity is a specific benefit covered by Medicare and many commercial plans. It runs up to 22 visits in a year through a primary care setting. Ask your clinic whether you qualify.
Lifestyle treatment rarely works alone long term for people with higher-class obesity. That is not a failure of willpower. The body defends its highest previous weight through changes in hunger hormones and metabolic rate.
Guidelines now recommend medication or surgery alongside lifestyle for many patients. The pairing tends to produce larger and more durable results than either approach alone.
Long-term outcomes depend as much on follow-up as on the starting treatment. Weight regain is common after any intervention without a maintenance plan. Monthly check-ins during the first year catch early regain, side effects, and changes in blood sugar or blood pressure.
Prescription weight-loss medications
Seven medications hold FDA approval for long-term weight management in adults. Two are newer GLP-1 injections, three are older oral combinations, one is an older injection, and one is for rare genetic obesity.
Eligibility is similar across the class. Most are approved for a BMI of 30 or higher. A BMI of 27 or higher qualifies if you have a weight-related condition like type 2 diabetes, high blood pressure, or high cholesterol.
GLP-1 receptor agonists
GLP-1 medications copy a gut hormone your body already makes after meals. The hormone tells your brain you are full, slows stomach emptying, and helps regulate blood sugar. Many patients describe the effect as “food noise getting quieter.”
Wegovy® (the brand of semaglutide) received FDA approval for chronic weight management in June 2021. In the Wegovy® STEP 1 trial, 1,961 adults on the 2.4 mg weekly dose lost an average of 14.9 percent of body weight over 68 weeks (NEJM 2021). The placebo group lost 2.4 percent.
Wegovy® also received a second FDA approval in March 2024. It now covers cardiovascular risk reduction in adults with overweight or obesity and established heart disease, based on the Wegovy® SELECT trial (n=17,604).
Zepbound® (the brand of tirzepatide) received FDA approval for chronic weight management in November 2023. In the Zepbound® SURMOUNT-1 trial, 2,539 adults on the 15 mg dose lost 20.9 percent of body weight over 72 weeks (NEJM 2022). The 10 mg dose produced 19.5 percent and the 5 mg dose 15.0 percent.
Zepbound® (tirzepatide) acts on two receptors at once (GIP and GLP-1). The dual mechanism appears to drive the larger weight loss numbers compared with Wegovy®.
Saxenda® (the brand of liraglutide) was FDA-approved in 2014 and is given as a daily injection. In the Saxenda® SCALE trial, 3,731 adults lost 8.0 percent of body weight over 56 weeks (NEJM 2015). It is rarely first line now that weekly options exist.
Common GLP-1 side effects are gastrointestinal. Nausea affects 40 to 44 percent of patients in trials. Vomiting, constipation, and diarrhea each affect 15 to 30 percent.
Most side effects improve after the first few weeks. Slow dose escalation and smaller meals reduce them further. Rare but serious risks include pancreatitis, gallbladder disease, and the thyroid concern flagged in the safety box above.
GLP-1 medications only keep working while you take them. Many patients regain much of the weight within a year of stopping, as shown in the Wegovy® STEP 4 and Zepbound® SURMOUNT-4 trials. Plan on a long-term medication relationship, not a short course.
Older weight-loss medications
Three combination pills and one short-term stimulant round out the non-GLP-1 options. They are cheaper, orally dosed, and sometimes the right match when GLP-1s are not.
Phentermine-topiramate (Qsymia®) was FDA-approved in 2012 for chronic weight management. In the CONQUER trial, adults on the top dose lost 9.8 percent of body weight over 56 weeks (Lancet 2011). Watch-outs include insomnia, tingling, and birth defect risk during pregnancy.
Naltrexone-bupropion (Contrave®) was FDA-approved in 2014. Trials showed 5 to 6 percent weight loss over 56 weeks (COR-I, Lancet 2010). It can raise blood pressure and is not used in uncontrolled hypertension or seizure history.
Orlistat (Xenical prescription, Alli over the counter) was FDA-approved in 1999. It blocks about 30 percent of dietary fat from being absorbed. Weight loss averages about 3 percent in a year, and the side effects are gastrointestinal and well known.
Phentermine alone (Adipex-P) was FDA-approved in 1959 and is labeled for short-term use up to 12 weeks. It is a DEA Schedule IV controlled substance. Some clinicians prescribe it longer off-label, but long-term safety data in that setting is limited.
Medications for rare genetic obesity
A small number of people carry inherited gene variants that disable normal appetite signaling. Setmelanotide (Imcivree®) was FDA-approved in 2020 for specific conditions: POMC, PCSK1, or LEPR deficiency, and Bardet-Biedl syndrome.
Genetic testing is required before starting. Most people with obesity do not carry these variants, so this option applies to a small group. If your family history or early-onset pattern raises the question, ask about referral to a genetic counselor.
Devices and endoscopic procedures
A middle ground between medication and surgery has grown over the last decade. These options work mechanically rather than chemically.
Intragastric balloon (Orbera, ReShape, Obalon) was FDA-approved in 2015. A soft balloon is placed in the stomach through an endoscope for six months, then removed. Weight loss averages about 10 percent during the six-month placement.
Endoscopic sleeve gastroplasty (ESG) reshapes the stomach with internal sutures and no incisions. In the MERIT trial, 209 adults lost 13.6 percent of body weight at 52 weeks (Lancet 2022). It is a newer option, and long-term data is still building.
Plenity (hydrogel capsules) received FDA clearance in 2019 as a prescription device, not a drug. The capsules expand in the stomach before meals and pass through normally. In the GLOW study, weight loss averaged 6.4 percent over 24 weeks, compared with 4.4 percent on placebo (Obesity 2019).
Each mechanical option has limits. Balloons typically come out at six months and weight often returns, while ESG results depend on the operator and the patient’s follow-up. Plenity is taken twice daily and stopped if it does not work after eight weeks.
Bariatric surgery
Bariatric surgery is the most effective obesity treatment available. It also carries the most up-front risk and the most lifestyle change.
The STAMPEDE trial enrolled 150 patients with type 2 diabetes and obesity. Gastric bypass produced greater diabetes remission than medical therapy alone at five years (NEJM 2017). Weight loss after surgery commonly reaches 25 to 30 percent of body weight in the first year.
Roux-en-Y gastric bypass reduces the stomach to a small pouch and reroutes a loop of small intestine. Results are strong and durable, and this procedure has the most long-term outcome data.
Sleeve gastrectomy removes about 80 percent of the stomach, leaving a sleeve-shaped pouch. It is now the most common bariatric procedure in the United States, with shorter operating time and comparable weight loss at one year.
Adjustable gastric band is a device placed around the upper stomach to limit intake. Use has declined sharply because newer procedures produce better weight loss with similar safety.
Who qualifies has shifted. ASMBS 2022 guidelines recommend surgery at a BMI of 35 or higher regardless of comorbidities. Surgery is also appropriate at a BMI of 30 to 34.9 with metabolic disease such as type 2 diabetes.
Surgery risks include bleeding, infection, leaks, and in the long term, nutrient deficiencies that require lifelong vitamin and mineral monitoring. A good bariatric program includes dietitian support, psychology screening, and a structured follow-up schedule for at least five years.
Outcomes depend heavily on the program, not only the procedure. Ask about the surgeon’s annual case volume, the readmission rate, and the plan for weight regain after year two. Centers of Excellence accreditation through the MBSAQIP program is a reasonable starting filter.
Questions to ask your doctor
Bring this list to your visit. Print it or pull it up on your phone. A focused conversation is the single best predictor of a plan that actually fits.
1. Given my BMI, health conditions, and history, which treatments am I a good candidate for?
2. What weight loss percentage is realistic with each option for someone like me?
3. What are the most common side effects, and what do the serious ones look like?
4. If we choose a medication, how long will I stay on it? What happens if I stop?
5. Does my insurance cover this option? If not, what are the out-of-pocket paths?
6. How often will we check in during the first year?
7. What will we track to know the treatment is working? (Weight, waist, labs, blood pressure.)
8. If lifestyle changes have not been enough for me before, how will we structure them this time?
9. Am I at risk for nutrient deficiencies, and do I need supplements or monitoring?
10. If this first plan does not work after three to six months, what is the next step?
Write down the answers during the appointment. Ask for anything in writing that you want to share with family or review later. Bring a partner or friend if the visit feels too dense to track alone.
A good clinician welcomes these questions. If yours rushes through them, it is reasonable to ask for a longer follow-up visit or a referral to an obesity medicine specialist.
How to prepare for the appointment
A little preparation changes the entire visit. Aim to walk in knowing your numbers, your history, and your goals.
- Pull your weight history. A rough graph of your weight over the last 10 to 20 years helps your doctor see the pattern.
- List what you have tried. Diets, programs, medications, supplements, and surgery. Include what worked, what did not, and for how long.
- Track a typical week of eating and activity. Even three to five days of notes is useful.
- Write down every medication and supplement you take. Some interact with weight-loss drugs.
- Bring any recent labs. A1c, lipid panel, liver panel, thyroid panel, and vitamin D are common starting points.
- Know your family history. Medullary thyroid cancer, pancreatitis, gallbladder disease, and eating disorders matter for safety.
- Define your goals in plain terms. “Walk without knee pain,” “come off blood pressure medication,” or “drop from Class II to Class I” are specific and measurable.
Talk to your doctor about any symptom that worries you, especially chest pain, severe abdominal pain, or thoughts of self-harm. Those conversations happen before any treatment plan does.
FREQUENTLY ASKED QUESTIONS
Bariatric surgery remains the most effective option by weight loss percentage, at 25 to 30 percent of body weight in the first year. Zepbound® (tirzepatide) is the most effective non-surgical option, producing 20.9 percent weight loss at the 15 mg dose in the Zepbound® SURMOUNT-1 trial (NEJM 2022). Effectiveness is only one factor; risk, durability, and fit matter just as much.
Most FDA-approved obesity medications are indicated at a BMI of 30 or higher. A BMI of 27 or higher also qualifies if you have a weight-related condition such as type 2 diabetes, high blood pressure, or high cholesterol. Your clinician confirms eligibility based on the specific drug label.
ASMBS 2022 guidelines recommend surgery at a BMI of 35 or higher regardless of comorbidities. Surgery is also appropriate at a BMI of 30 to 34.9 when type 2 diabetes or other metabolic disease is present. Older thresholds that required a BMI of 40 are no longer the standard for most programs.
Obesity is a chronic disease, so the language of “cure” rarely fits. Current guidelines aim for long-term management with sustained weight loss of 5 to 15 percent or more, durable remission of related conditions like type 2 diabetes, and improved quality of life. Bariatric surgery produces the most durable results, but lifelong follow-up is still standard.
Most patients regain a large share of the lost weight within a year of stopping. The Wegovy® STEP 4 and Zepbound® SURMOUNT-4 trials documented this pattern. GLP-1s are typically planned as long-term therapy, similar to medications for high blood pressure or high cholesterol.
GLP-1 medications have more than five years of post-approval safety data for type 2 diabetes and growing long-term data for obesity. Older medications like phentermine-topiramate and orlistat have decades of use. No obesity medication is risk-free, and regular follow-up catches problems early.
Zepbound® (tirzepatide) is the newest FDA-approved obesity medication, approved in November 2023. Endoscopic sleeve gastroplasty (ESG) is the newest non-drug option to accumulate large trial data, with MERIT results published in the Lancet in 2022. Both show how fast obesity care is moving, so ask your doctor what is currently approved for your situation.
Coverage varies by plan and by treatment. Medicare covers Intensive Behavioral Therapy for obesity and certain bariatric procedures. Most commercial plans cover bariatric surgery with prior authorization. GLP-1 coverage for obesity is inconsistent, with some plans covering Wegovy® or Zepbound® and others excluding them. Your plan’s formulary and your clinician’s prior authorization skills matter more than the drug itself.
Next Step
Ready to explore GLP-1 access?
If you and your doctor are considering a GLP-1 medication, our independent review compares every live telehealth option on evidence, clinical support, and access.
→ See the GLP-1 provider comparison
SOURCES
1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM 2021;384(11):989-1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM 2022;387:205-216. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
3. Pi-Sunyer X et al. A Randomized Controlled Trial of 3.0 mg Liraglutide (SCALE). NEJM 2015;373:11-22. https://www.nejm.org/doi/full/10.1056/NEJMoa1411892
4. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). NEJM 2023;389:2221-2232. https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
5. Wing RR et al. Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes (Look AHEAD). NEJM 2013;369:145-154. https://www.nejm.org/doi/full/10.1056/NEJMoa1212914
6. Gadde KM et al. Effects of Low-Dose, Controlled-Release Phentermine plus Topiramate (CONQUER). Lancet 2011;377:1341-1352. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)60205-5/fulltext
7. Greenway FL et al. Effect of Naltrexone plus Bupropion on Weight Loss (COR-I). Lancet 2010;376:595-605. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)60888-4/fulltext
8. Schauer PR et al. Bariatric Surgery versus Intensive Medical Therapy for Diabetes, 5-Year Outcomes (STAMPEDE). NEJM 2017;376:641-651. https://www.nejm.org/doi/full/10.1056/NEJMoa1600869
9. Abu Dayyeh BK et al. Endoscopic Sleeve Gastroplasty for Obesity (MERIT). Lancet 2022;400:441-451. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)01280-6/fulltext
10. Greenway FL et al. A Randomized, Double-Blind, Placebo-Controlled Study of Gelesis100 for Weight Loss (GLOW). Obesity (Silver Spring) 2019;27(2):205-216. https://pmc.ncbi.nlm.nih.gov/articles/PMC6587502/
11. Eisenberg D et al. 2022 ASMBS/IFSO Guidelines on Indications for Metabolic and Bariatric Surgery. SOARD 2022. https://www.soard.org/article/S1550-7289(22)00641-4/fulltext
12. CDC, NCHS Data Brief No. 508. Prevalence of Obesity and Severe Obesity Among Adults: United States, 2017 to March 2020. https://www.cdc.gov/obesity/php/data-research/adult-obesity-facts.html
13. Garvey WT et al. AACE/TOS Guidelines for Medical Care of Patients with Obesity. Endocrine Practice 2022. https://pro.aace.com/clinical-guidance
Last updated: 2026-06-17 · Editorially reviewed by the Peptides.io team
Important notices & disclaimers
Editorial & medical: This guide is general education, not medical advice. Talk to a licensed clinician before starting, stopping, or changing any medication.
Affiliate disclosure: Peptides.io may earn a commission from links to providers — it never changes what you pay or how we rank them, and never influences our recommendations.
Compounded GLP-1 (FDA): Compounded semaglutide and tirzepatide are not FDA-approved and have not been evaluated by the FDA for safety, effectiveness, or quality. They are not generic versions of, or equivalent to, branded medications such as Ozempic®, Wegovy®, Mounjaro®, or Zepbound®. Clinical-trial results cited here apply only to those branded formulations — not to compounded preparations.
Comments